George Stanley, Medical Director for the UK & Ireland at BioCryst Shares Insights from Long-Term Study Data at EAACI 2022

Shots: George spoke about the 96-week data from the P-III APeX-2 trial evaluating BioCryst’s lead candidate in Hereditary Angioedema (HAE)  He also talked about various patient support programs from BioCryst to help patients with self-management of their HAE The interview gives an understanding of BioCryst’s vision to develop medicines that treat rare diseases for unmet…